Evidence map›Paper›PMID 40686542›Full record

ArticleACS pharmacology & translational science2025

Harnessing Telodendrimer Nanotraps in Nanogels for Systemic Immune Modulation in Sepsis Treatment.

Xiaotian Ji, Changying Shi, Dekai Yuan, Minghao Luo, Liye Suo, Xiguang Yang, Dandan Guo, Norifumi Urao, Robert Cooney, Juntao Luo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaotian Ji†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Changying Shi†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Dekai Yuan†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Minghao Luo†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Liye Suo†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Xiguang Yang†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Dandan Guo†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Norifumi Urao†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Robert Cooney†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.
Juntao Luo†Department of Pharmacology, ‡Department of Pathology, §Department of Surgery, ∥Upstate Sepsis Interdisciplinary Research Center, ⊥Department of Microbiology and Immunology, #Upstate Cancer Center, State University of New York Upstate Medical University, Syracuse, New York 13210, United States.ORCID https://orcid.org/0000-0002-3538-9453

Funding

Impact of hematopoietic stem progenitor cell dysfunction on tissue recovery from ischemic injury in metabolic syndromeR01DK111489 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI URAO, NORIFUMI · 2017 to 2021
$2.0M
Targeting neutrophil clearance to harness myeloid responses for wound healing.R01GM144624 · NIGMS · UPSTATE MEDICAL UNIVERSITY · PI URAO, NORIFUMI · 2023 to 2024
$826k
NIDDK NIH HHS R01 DK111489NIGMS NIH HHS R01 GM144624
6 · The paper itself

Abstract

Sepsis is featured by uncontrolled life-threatening systemic inflammatory responses to infection and tissue damage. Spontaneous attenuation of a broad spectrum of septic molecules and cytokines is promising for effective sepsis treatment. We have developed a functionalized nanosized hydrogel, i.e., nanogel (NG), via a one-pot precipitation polymerization using biocompatible, biodegradable monomers/cross-linkers and versatile polymerizable functional telodendrimer (TD) nanotraps (NTs) for effective scavenging of septic molecules. The telodendrimer nanogel (TD-NG) has a spherical morphology with a homogeneous size distribution around 300 nm. TD-NG is stable in plasma and can be degraded in the presence of reducing agents, e.g., intracellular glutathione. The size-exclusive nanogel network and the polyethylene glycol (PEG) shell coating exclude the abundant serum proteins for selective and effective capture of septic molecules, e.g., lipopolysaccharide (LPS), tumour necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and IL-6. PEGylated TD-NGs are nontoxic in cell culture with low immune cell uptake and biocompatible after iv injection with prolonged circulation time and majority elimination into feces via liver bile ducts. Systemic administration of TD-NG significantly inhibits LPS-induced NF-κB activation and cytokine production. PEGylated TD-NGs effectively attenuate inflammatory molecules in situ for effective immune modulation, which ameliorates tissue damage and improves the survival rate in severe sepsis mouse models induced by cecum ligation and puncture.

Indexed as

cytokine adsorptionendotoxin removalimmune modulationnanogelsepsis treatmenttelodendrimer nanotrap

Identifiers

PMID40686542
PMCPMC12273109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.